PKO Investment Management Joint Stock Co Grows Stock Position in Edwards Lifesciences Co. (NYSE:EW)

PKO Investment Management Joint Stock Co raised its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 112.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,000 shares of the medical research company's stock after purchasing an additional 9,000 shares during the quarter. PKO Investment Management Joint Stock Co's holdings in Edwards Lifesciences were worth $1,232,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Chicago Capital LLC boosted its position in shares of Edwards Lifesciences by 8.5% during the 1st quarter. Chicago Capital LLC now owns 19,971 shares of the medical research company's stock valued at $1,447,000 after purchasing an additional 1,563 shares in the last quarter. Inscription Capital LLC acquired a new stake in Edwards Lifesciences in the first quarter worth $1,740,000. QRG Capital Management Inc. increased its stake in Edwards Lifesciences by 7.8% in the first quarter. QRG Capital Management Inc. now owns 83,294 shares of the medical research company's stock valued at $6,037,000 after purchasing an additional 5,992 shares in the last quarter. Brighton Jones LLC raised its holdings in shares of Edwards Lifesciences by 22.1% during the first quarter. Brighton Jones LLC now owns 4,380 shares of the medical research company's stock valued at $317,000 after purchasing an additional 793 shares during the period. Finally, Exchange Traded Concepts LLC boosted its position in shares of Edwards Lifesciences by 66.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 21,095 shares of the medical research company's stock worth $1,529,000 after purchasing an additional 8,453 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on EW shares. Wall Street Zen downgraded Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Piper Sandler upped their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 13th. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a report on Friday, April 25th. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Finally, Robert W. Baird upped their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a report on Thursday, April 24th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $80.20.

Edwards Lifesciences Stock Performance

EW stock traded down $1.51 during midday trading on Tuesday, hitting $73.31. The company's stock had a trading volume of 3,002,914 shares, compared to its average volume of 5,223,360. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The stock has a market cap of $43.00 billion, a price-to-earnings ratio of 10.52, a PEG ratio of 4.82 and a beta of 1.12. The stock's 50-day moving average price is $74.70 and its 200 day moving average price is $72.96. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter in the previous year, the firm posted $0.66 EPS. Edwards Lifesciences's revenue was up 6.2% on a year-over-year basis. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the sale, the insider now owns 206,900 shares in the company, valued at approximately $15,565,087. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $74.91, for a total value of $447,961.80. Following the transaction, the chief executive officer now owns 58,284 shares in the company, valued at $4,366,054.44. This trade represents a 9.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 51,898 shares of company stock worth $3,796,154. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.